Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the ability of eltrombopag to maintain a platelet
count sufficient to facilitate initiation of antiviral therapy, to minimise antiviral therapy
dose reductions and to avoid permanent discontinuation of antiviral therapy. The clinical
benefit of eltrombopag will be measured by the proportion of subjects who are able to achieve
a Sustained Virological Response (SVR).